reports
Man Group PLC : Form 8.3 - Picton Property Income Limited
Man Group PLC : Form 8.3 - Picton Property Income Limited FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant...
Man Group PLC : Form 8.3 - LondonMetric Property Plc
Man Group PLC : Form 8.3 - LondonMetric Property Plc FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant secu...
Parsons to Present at the Barclays 43rd Annual Industrial Select Confe...
Parsons to Present at the Barclays 43rd Annual Industrial Select Conference CHANTILLY, Va., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE: PSN) announced today that Carey Smith, chair, president, and chief executive officer, and Matt Ofilos, chief financial officer, will participate in a fireside chat question and answer session at the Barclays 43rd Annual Industrial Select Conference on Wednesday, February 18, 2026, at approximately 3:35 p.m. Eastern Time. The presentation will be available live via webcast on the investor relations section of Parsons’ website (). A replay...
Magnum Ice Cream Company N.V: 6 directors
Six Directors at Magnum Ice Cream Company N.V bought 90,981 shares at 16.050USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Oncolytics Biotech Inc: 9 directors
Nine Directors at Oncolytics Biotech Inc bought 289,232 shares at between 0.827USD and 0.859USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...
Lanka Realty Investments Plc: 2 directors
Two Directors at Lanka Realty Investments Plc bought/maiden bought 250,000 shares at between 54.000LKR and 54.028LKR. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...
Costamare Bulkers Holdings Limited Sets the Date for its Fourth Quarte...
Costamare Bulkers Holdings Limited Sets the Date for its Fourth Quarter 2025 Results Release, Conference Call and Webcast Earnings Release: Friday, February 20, 2026, Before Market OpensConference Call and Webcast: Friday, February 20, 2026, at 8:30 a.m. ET MONACO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Costamare Bulkers Holdings Limited (NYSE:CMDB) (“Costamare Bulkers” or the “Company”), announced today that it will release its results for the fourth quarter ended December 31, 2025 before the market opens in New York on February 20, 2026. Conference Call Details: On Friday, February 20, 2...
Aktieselskabet Schouw & Co.: Written Resolution of Bondholders passed
Aktieselskabet Schouw & Co.: Written Resolution of Bondholders passed 13 February 2026: Reference is made to the announcement made by Aktieselskabet Schouw & Co. (the "Issuer") on 6 February 2026 regarding the summons for a Written Resolution (the "Summons") pursuant to the bond terms dated 14 June 2024 (as amended) (the "Bond Terms") for the Issuer's FRN senior unsecured bond issue maturing in 2029 (ISIN NO0013260349) (the "Bonds"). The Proposal (as defined in the Summons) to accept the release of BioMar as an Original Guarantor and Material Subsidiary under the Bond Terms, in the event t...
Gentian Diagnostics AS: 2 directors
A director at Gentian Diagnostics AS bought 2,500 shares at 40.000NOK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Moleculin Launches CEO Corner Platform to Share Strategic Insights
Moleculin Launches CEO Corner Platform to Share Strategic Insights CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner...
The Marketing Alliance Announces Financial Results for Fiscal Third Qu...
The Marketing Alliance Announces Financial Results for Fiscal Third Quarter Ended December 31, 2025 ST. LOUIS, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 third quarter ended December 31, 2025. Q3 FY2026 Financial Key Items (all comparisons to the prior year quarter) Revenues from operations were $5,018,127 compared to $4,550,421, an increase of over 10% which was driven by an increase in revenue from the insurance distribution businessOperating income from continuing opera...
Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share o...
Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock OLD GREENWICH, Conn., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (Nasdaq: STRR and STRRP) ("Star" or the "Company"), formerly Hudson Global, Inc. (Nasdaq: HSON and HSONP), a diversified holding company, announced today that its Board of Directors declared a cash dividend to holders of the Company’s 10% Series A Cumulative Perpetual Preferred Stock of $0.25 per share. The record date for this dividend is March 1, 2026, and the payment date is March 10,...
Sienna Announces February Dividend
Sienna Announces February Dividend MARKHAM, Ontario, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of February 2026, representing $0.936 per Common Share on an annualized basis. The dividend will be payable on March 13, 2026 to shareholders of record as at February 27, 2026. The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada)...
Olenox Industries Announces Settlement Agreement with Cedar Advance LL...
Olenox Industries Announces Settlement Agreement with Cedar Advance LLC CONROE, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- via IBN – (NASDAQ: OLOX) ("Olenox" or the "Company") today announced that it has reached a mutual settlement agreement with Cedar Advance LLC ("Cedar"), resolving the outstanding amounts owed to Cedar pursuant to the Standard Merchant Cash Advance Agreements between the Company and Cedar. Under the terms of the Settlement and Release agreement, fully executed on Feb. 10, 2026, the Company has agreed to issue Cedar restricted shares of Company common stock at market pr...
HCW Biologics and WY Biotech Announce Closing of First Round of Financ...
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune HCW Biologics receiving cash fee and co-founder shares in Trimmunevalued at $7.0 million Trimmune will hold exclusive worldwide license for rights to high potential preclinical molecule created with HCW Biologics’ TRBC drug development platform Initiation of Phase 1 clinical study expected in the first half of 2027 HCW Biologics retains royalty-free option to reclaim the rights to the Americas territory MIRAMAR, Fla., Feb. 13, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“...
SaverOne Expands Global Collaboration with Cemex
SaverOne Expands Global Collaboration with Cemex Completed European Installation Milestones & Advancing to Additional Regions Petah Tikvah, Israel, Feb. 13, 2026 (GLOBE NEWSWIRE) -- SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in transportation safety solutions, today announced the completion of the installation of its Driver Distraction Prevention System (DDPS) in Cemex Croatia, the fifth country where Cemex have assimilated SaverOne’s safety system, joining Spain, Germany, the Czech Republic and Israel. This milestone concludes a key phase in SaverO...
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Ap...
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technolog...
- ABGSC Construct. & Real Estate Research
- Julia Sundvall
- Simon Jönsson
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.